E. Kennedy

发表

Defining Treatment and Outcomes of Hepaticojejunostomy Failure Following Pancreaticoduodenectomy

L. Koniaris, C. Yeo, J. Winter, 2013, Journal of Gastrointestinal Surgery.

Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: Implications for tumor progression and clinical outcome

M. Lisanti, C. Yeo, A. Witkiewicz, 2008, Cell cycle.

Implementation of a Critical Pathway for Distal Pancreatectomy at an Academic Institution

Charles J. Yeo, Adam C. Berger, Karen A. Chojnacki, 2009, Journal of Gastrointestinal Surgery.

Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: Interim analysis.

B. Somer, D. Munn, C. Link, 2016 .

Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer.

C. Link, N. Bahary, E. Kennedy, 2016 .

Single nucleotide polymorphism in RECQL and survival in resectable pancreatic adenocarcinoma.

R. Gibbs, D. Muzny, S. Scherer, 2009, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod

C. James, R. Stupp, D. Wainwright, 2018, Journal of Neuro-Oncology.

Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil: Is it time to move forward?

S. Kern, C. Yeo, T. Showalter, 2008, Cancer biology & therapy.

Impact of obesity on perioperative morbidity and mortality after pancreaticoduodenectomy.

T. Hyslop, C. Yeo, A. Berger, 2009, Journal of the American College of Surgeons.

Impact of Obesity on Perioperative Morbidity and Mortality Following Pancreaticoduodenectomy

T. Hyslop, C. Yeo, A. Berger, 2018 .

QS31. Impact of Obesity On Perioperative Morbidity and Mortality Following Pancreaticoduodenectomy (PD)

A. Berger, P. Sauter, E. Rosato, 2008 .

Dunking pancreaticojejunostomy versus duct-to-mucosa anastomosis

C. Yeo, E. Kennedy, 2011, Journal of hepato-biliary-pancreatic sciences.

A phase 2 study of docetaxel in combination with indoximod in metastatic breast cancer.

W. J. Ramsey, C. Link, S. Antonia, 2014 .

Safety of perioperative aspirin therapy in pancreatic operations.

C. Yeo, J. Winter, C. McIntyre, 2014, Surgery.

A Dual-Institution Randomized Controlled Trial of Remnant Closure after Distal Pancreatectomy: Does the Addition of a Falciform Patch and Fibrin Glue Improve Outcomes?

T. Hyslop, C. Yeo, Wei Phin Tan, 2012, Journal of Gastrointestinal Surgery.

A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma.

N. Agarwal, C. Drake, C. Link, 2019, The oncologist.

Pancreaticoduodenectomy with extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma.

C. Yeo, E. Kennedy, 2007, Surgical oncology clinics of North America.

CD4+ T Cells Pass Through an Effector Phase During the Process of In Vivo Tolerance Induction

C. Drake, D. Pardoll, D. Huso, 2003, The Journal of Immunology.

The Influence of Prognostic Factors and Adjuvant Chemoradiation on Survival After Pancreaticoduodenectomy for Ampullary Carcinoma

C. Yeo, T. Showalter, A. Berger, 2011, Journal of Gastrointestinal Surgery.

Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.

B. Somer, C. Link, J. S. Lee, 2018 .

Tolerance Induction Phase During the Process of In Vivo T Cells Pass Through an Effector + CD 4

C. Drake, D. Pardoll, D. Huso, 2003 .

Intraductal Papillary Mucinous Neoplasm (IPMN) with Extra-Pancreatic Mucin: A Case Series and Review of the Literature

C. Yeo, A. Witkiewicz, E. Kennedy, 2012, Journal of Gastrointestinal Surgery.

Does type of pancreaticojejunostomy after pancreaticoduodenectomy decrease rate of pancreatic fistula? A randomized, prospective, dual-institution trial.

K. Lillemoe, H. Pitt, T. Hyslop, 2009, Journal of the American College of Surgeons.

Reoperative completion pancreatectomy for suspected malignant disease of the pancreas.

C. Yeo, P. Sauter, E. Rosato, 2011, The Journal of surgical research.

Reconstruction Following the Pylorus Preserving Whipple Resection: PJ, HJ, and DJ

C. Yeo, E. Kennedy, J. Brumbaugh, 2010, Journal of Gastrointestinal Surgery.

514 Results of Phase 1b trial of the Indoleamine 2,3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma

D. Munn, C. Link, Y. Zakharia, 2015 .

Initiation of a critical pathway for pancreaticoduodenectomy at an academic institution--the first step in multidisciplinary team building.

C. Yeo, I. Marino, A. Berger, 2007, Journal of the American College of Surgeons.

Trial watch: IDO inhibitors in cancer therapy

L. Zitvogel, L. Galluzzi, G. Kroemer, 2014, Oncoimmunology.

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

C. Drake, D. Pardoll, W. Nelson, 2005, Cancer cell.

Genetics of colorectal cancer.

E. P. Kennedy, E. Kennedy, S. Hamilton, 1998, Seminars in surgical oncology.

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

K. Morrissey, D. Munn, C. Link, 2018, Journal of Immunotherapy for Cancer.

PDCT-06. RADIO-IMMUNOTHERAPY USING THE IDO-INHIBITOR INDOXIMOD IN COMBINATION WITH RE-IRRADIATION FOR CHILDREN WITH PROGRESSIVE BRAIN TUMORS IN THE PHASE 1 SETTING: AN UPDATED REPORT OF SAFETY AND TOLERABILITY (NCT02502708)

T. MacDonald, D. Munn, I. Heger, 2017 .

Abstract CT117: Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma

D. Munn, R. McWilliams, C. Link, 2017 .

ACTR-53. INTERIM ANALYSIS OF PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY INHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS

D. Munn, C. Link, Y. Zakharia, 2016 .

Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma.

D. Munn, R. McWilliams, C. Link, 2016 .

Renal Cell Carcinoma Metastatic to the Duodenum: Treatment by Classic Pancreaticoduodenectomy and Review of the Literature

C. Yeo, A. Witkiewicz, R. Adamo, 2008, Journal of Gastrointestinal Surgery.

Perioperative surgical care bundle reduces pancreaticoduodenectomy wound infections.

B. Leiby, C. Yeo, P. Sauter, 2012, The Journal of surgical research.

Abstract CT151: A Phase II study of NLG207 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer

P. Thaker, C. Link, Austin Miller, 2019, Clinical Trials.

Optimal Technical Management of Stump Closure Following Distal Pancreatectomy: A Retrospective Review of 215 Cases

Lisa J. Harris, H. Abdollahi, C. Yeo, 2010, Journal of Gastrointestinal Surgery.

Is Gastrectomy Safe in the Elderly? A Single Institution Review

H. Abdollahi, C. Yeo, A. Berger, 2011 .

Serum Blood Urea Nitrogen and Serum Albumin on the First Postoperative Day Predict Pancreatic Fistula and Major Complications After Pancreaticoduodenectomy

B. Leiby, N. Richards, C. Yeo, 2013, Journal of Gastrointestinal Surgery.

Preoperative mechanical bowel preparation does not offer a benefit for patients who undergo pancreaticoduodenectomy.

B. Leiby, C. Yeo, P. Sauter, 2010, Surgery.

Giant Splenic Artery Pseudoaneurysm

C. Yeo, W. Maley, H. Lavu, 2011, Journal of Gastrointestinal Surgery.

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

D. Munn, R. McWilliams, R. Kolhe, 2021, Journal for ImmunoTherapy of Cancer.

Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial.

N. Ibrahim, C. Link, P. Dillon, 2020, JAMA oncology.

A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

B. Leiby, C. Yeo, T. George, 2020, Annals of surgery.

Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future

N. Richards, C. Yeo, S. Showalter, 2010, Expert opinion on drug delivery.

The case for routine use of adjuvant therapy in pancreatic cancer

C. Yeo, E. Kennedy, 2007, Journal of surgical oncology.

Does Resident Experience Affect Outcomes in Complex Abdominal Surgery? Pancreaticoduodenectomy as an Example

C. Yeo, J. Winter, R. Burkhart, 2014, Journal of Gastrointestinal Surgery.

A phase I/II study of the combination of indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors.

D. Munn, H. Colman, C. Link, 2014 .

Tumor recurrence is independent of pancreatic fistula in patients after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.

B. Leiby, C. Yeo, A. Berger, 2013, Journal of the American College of Surgeons.

Surgical Apgar Score Predicts Perioperative Morbidity in Patients Undergoing Pancreaticoduodenectomy at a High-Volume Center

B. Leiby, C. Yeo, A. Berger, 2012, Journal of Gastrointestinal Surgery.

Margin Positive Pancreaticoduodenectomy Is Superior to Palliative Bypass in Locally Advanced Pancreatic Ductal Adenocarcinoma

B. Leiby, C. Yeo, A. Berger, 2009, Journal of Gastrointestinal Surgery.

Synchronous autoimmune pancreatitis and infiltrating pancreatic ductal adenocarcinoma: case report and review of the literature.

R. Hruban, C. Yeo, A. Witkiewicz, 2008, Human pathology.

The Novel Triad of Dorsal Agenesis of the Pancreas with Concurrent Pancreatic Ductal Adenocarcinoma and Nonalcoholic Chronic Calcific Pancreatitis: A Case Series and Review of the Literature

C. Yeo, P. Sauter, H. Lavu, 2011, Journal of Gastrointestinal Surgery.

The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.

M. Gorospe, C. L. Costantino, C. Yeo, 2009, Cancer research.

Extended Follow-Up and Outcomes of Patients Undergoing Pancreaticoduodenectomy for Nonmalignant Disease

C. Yeo, D. Loren, A. Siddiqui, 2011, Journal of Gastrointestinal Surgery.

Symptom Clusters in Patients With Pancreatic Cancer Undergoing Surgical Resection: Part II.

B. Leiby, C. Yeo, Sherry A Burrell, 2018, Oncology nursing forum.

Preoperative drainage in pancreatic cancer.

C. Yeo, E. Rosato, E. Kennedy, 2010, The New England journal of medicine.

Operative Anatomy, 3rd ed.

E. Kennedy, 2009 .

Commentary: Two stage pancreaticojejunostomy in pancreaticoduodenectomy: a retrospective analysis of short-term results.

C. Yeo, E. Kennedy, 2008, American journal of surgery.

HuR Status is a Powerful Marker for Prognosis and Response to Gemcitabine-Based Chemotherapy for Resected Pancreatic Ductal Adenocarcinoma Patients

G. Gonye, H. Rui, N. Richards, 2010, Annals of surgery.

Preoperative Imaging for Resectable Periampullary Cancer: Clinicopathologic Implications of Reported Radiographic Findings

L. Koniaris, D. Mitchell, C. Yeo, 2013, Journal of Gastrointestinal Surgery.

A Prospective Randomized Double Blind Placebo Controlled Trial on the Efficacy of Ethanol Celiac Plexus Neurolysis in Patients with Operable Pancreatic and Periampullary Adenocarcinoma

B. Leiby, C. Yeo, Sherry A Burrell, 2014, Journal of the American College of Surgeons.

Chapter 58B – Pancreatic cancer: Clinical aspects, assessment, and management

C. Yeo, E. Kennedy, 2012 .

A progressive postresection walking program significantly improves fatigue and health-related quality of life in pancreas and periampullary cancer patients.

B. Leiby, C. Yeo, Sherry A Burrell, 2012, Journal of the American College of Surgeons.

Symptom Clusters in Patients With Pancreatic Cancer Undergoing Surgical Resection: Part I.

B. Leiby, C. Yeo, Sherry A Burrell, 2018, Oncology nursing forum.

Non-neoplastic Epithelial Cysts of the Pancreas: A Rare, Benign Entity

C. Yeo, Nidhi Agrawal, J. Winter, 2014, Journal of Gastrointestinal Surgery.

Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.

D. Munn, R. McWilliams, C. Link, 2018 .

346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors

K. Morrissey, D. Munn, C. Link, 2015 .

Abstract CT004: Front-line therapy of DIPG using the IDO pathway inhibitor indoximod in combination with radiation and chemotherapy

T. MacDonald, D. Munn, I. Heger, 2018, Clinical Trials.

IMCT-21UPDATES ON PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY IHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS

D. Munn, H. Colman, C. Link, 2015 .

A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma.

N. Agarwal, C. Drake, C. Link, 2020 .

A progressive postresection walking program significantly improves fatigue and health-related quality of life in pancreas and periampullary cancer patients.

B. Leiby, C. Yeo, Sherry A Burrell, 2012, Journal of the American College of Surgeons.

Abstract P2-11-09: A phase 2 randomized trial of the IDO pathway inhibitor indoximod in combination with taxane based chemotherapy for metastatic breast cancer: Preliminary data

D. Munn, C. Link, E. Kennedy, 2016 .